Neurocrine Biosciences (NASDAQ:NBIX) PT Raised to $216.00 at Oppenheimer

Neurocrine Biosciences (NASDAQ:NBIX) had its price target boosted by Oppenheimer from $200.00 to $216.00 in a research report released on Thursday, Benzinga reports. Oppenheimer currently has an outperform rating on the stock.

A number of other research firms also recently issued reports on NBIX. Mizuho lifted their price target on shares of Neurocrine Biosciences from $116.00 to $140.00 and gave the company a neutral rating in a research report on Thursday, February 8th. JPMorgan Chase & Co. boosted their target price on Neurocrine Biosciences from $148.00 to $158.00 and gave the stock an overweight rating in a research report on Wednesday, March 20th. Needham & Company LLC restated a hold rating on shares of Neurocrine Biosciences in a research report on Wednesday. StockNews.com upgraded shares of Neurocrine Biosciences from a buy rating to a strong-buy rating in a research report on Thursday, February 8th. Finally, The Goldman Sachs Group raised their target price on shares of Neurocrine Biosciences from $134.00 to $153.00 and gave the company a buy rating in a report on Thursday, January 25th. Six investment analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the stock. According to data from MarketBeat.com, Neurocrine Biosciences has a consensus rating of Moderate Buy and an average price target of $147.88.

Neurocrine Biosciences Trading Up 0.6 %

Shares of Neurocrine Biosciences stock traded up $0.88 during trading hours on Thursday, hitting $140.71. 616,567 shares of the company were exchanged, compared to its average volume of 795,508. The business has a 50-day moving average of $137.37 and a 200-day moving average of $128.78. Neurocrine Biosciences has a 1 year low of $89.04 and a 1 year high of $148.37. The stock has a market capitalization of $14.16 billion, a price-to-earnings ratio of 38.76 and a beta of 0.28.

Neurocrine Biosciences (NASDAQ:NBIX) last announced its quarterly earnings data on Wednesday, February 7th. The company reported $1.44 EPS for the quarter, topping analysts’ consensus estimates of $1.13 by $0.31. The company had revenue of $515.20 million during the quarter, compared to the consensus estimate of $518.52 million. Neurocrine Biosciences had a net margin of 18.65% and a return on equity of 17.45%. Neurocrine Biosciences’s quarterly revenue was up 25.0% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.88 EPS. As a group, research analysts anticipate that Neurocrine Biosciences will post 4.79 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, insider Eric Benevich sold 19,818 shares of the business’s stock in a transaction on Monday, April 15th. The shares were sold at an average price of $133.36, for a total transaction of $2,642,928.48. Following the completion of the sale, the insider now directly owns 40,778 shares of the company’s stock, valued at approximately $5,438,154.08. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In other Neurocrine Biosciences news, insider David W. Boyer sold 1,328 shares of the business’s stock in a transaction that occurred on Thursday, February 8th. The shares were sold at an average price of $135.41, for a total transaction of $179,824.48. Following the completion of the sale, the insider now directly owns 4,895 shares in the company, valued at $662,831.95. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Eric Benevich sold 19,818 shares of the stock in a transaction on Monday, April 15th. The stock was sold at an average price of $133.36, for a total transaction of $2,642,928.48. Following the completion of the sale, the insider now directly owns 40,778 shares of the company’s stock, valued at approximately $5,438,154.08. The disclosure for this sale can be found here. Over the last three months, insiders have sold 181,547 shares of company stock valued at $25,039,887. Insiders own 4.30% of the company’s stock.

Institutional Trading of Neurocrine Biosciences

A number of institutional investors have recently added to or reduced their stakes in NBIX. FCF Advisors LLC purchased a new stake in shares of Neurocrine Biosciences during the fourth quarter valued at approximately $1,157,000. abrdn plc lifted its holdings in Neurocrine Biosciences by 2,503.0% in the 4th quarter. abrdn plc now owns 83,633 shares of the company’s stock worth $11,019,000 after buying an additional 80,420 shares in the last quarter. Redhawk Wealth Advisors Inc. purchased a new position in Neurocrine Biosciences in the 4th quarter valued at about $1,245,000. HealthInvest Partners AB acquired a new stake in shares of Neurocrine Biosciences during the fourth quarter valued at about $1,662,000. Finally, Roman Butler Fullerton & Co. purchased a new stake in shares of Neurocrine Biosciences during the fourth quarter worth about $1,256,000. 92.59% of the stock is owned by hedge funds and other institutional investors.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.